Home
Resources
Follow portfolio news
...

Two new awards further establish WuXi Biologics as a leading player in biopharmaceuticals

Published on
1/4/2025
Amended on
23/3/2026
0
minute(s)
Odyssey 2021
Wuxi Biologics
General Atlantic 's Chinese business has once again been recognized by Morningstar Sustainalytics and the CDMO Leadership Awards as a leading ESG company. With over 12,000 employees worldwide, the biopharmaceutical specialist, which is included in the Vintage FPCI Altaroc Odyssey 2021, continues to highlight the importance of transforming the pharmaceuticals market.
By
Antoine Orsoni
Antoine Orsoni
Two new awards further establish WuXi Biologics as a leading player in biopharmaceuticals
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
Questo articolo è stato tradotto automaticamente. Ci scusiamo per eventuali inesattezze o errori di traduzione.

WuXi Biologics has been recognized by Morningstar Sustainalytics as a leading ESG (environmental, social and governance) company in 2025, for the fifth year running. Ranked in the top 1% of companies in the pharmaceutical sector, this distinction underlines the company's pioneering role in sustainable and responsible practices. The company was judged on key elements of the sector. Sustainalytics analyzes the material risks faced by companies in their sector, in this case biopharmaceuticals. The assessment also looks at how WuXi Biologics manages these risks, notably through sustainable and responsible practices. The Chinese specialist was also awarded the " CDMO Leadership Award ", for the 8th year running (CDMOs are organizations responsible for the outsourced manufacture of drug substances, and the innovation and development process preceding manufacture). The CDMO Leadership Awards are presented by Outsourced Pharma and Life Science Leader. For the 2025 edition, more than 200 CDMOs were assessed on the basis of an independent study, and WuXi came out on top again. A few months ago, the Dow Jones Sustainability 2024 index rewarded the company.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, said, "We are honored to receive this distinction again, which reflects our ongoing commitment to sustainability." The company has also distinguished itself through notable achievements, such as its EcoVadis Platinum Medal (the most widely acclaimed sustainability and corporate social responsibility rating organization, with over 130,000 companies assessed worldwide and present in the Vintage FPCI Altaroc Odyssey 2021), and its MSCI AAA rating (the highest rating that rewards a company's management of ESG risks and opportunities).

WuXi Biologics implements innovative solutions to reduce its ecological footprint while supporting its partners in their ESG commitments. WuXi Biologics is listed in the United Nations Global Compact as an example of sustainable development, and is included in the FTSE4Good and Hang Seng ESG 50 indices.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
Rest of the world
Healthcare
Welcome to Altaroc
To provide you with a tailored experience, we invite you to complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
Your investor profile
Financial intermediary or Professional investor
Financial advisors, wealth management advisors, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced Investor or Altaroc Investor
Private investors who have already invested in Altaroc who have a minimum investment capacity of €100,000.
Private investors who have already invested in Altaroc who have a minimum investment capacity of €250,000.
Inexperienced investor
Individual investors with an investment capacity of less than €100,000.
Individual investors with an investment capacity of less than €250,000.
Institutional investor
Pension funds, retirement funds, asset management firms, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.